ASX - By Stock
|
ATH |
Re:
Ann: Appendix 4E Preliminary Final Report
|
|
Mateo335
|
11 |
3.4K |
5 |
30/08/24 |
30/08/24 |
ASX - By Stock
|
11
|
3.4K
|
5
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Appendix 4E Preliminary Final Report
|
|
Mateo335
|
11 |
3.4K |
8 |
29/08/24 |
29/08/24 |
ASX - By Stock
|
11
|
3.4K
|
8
|
|
ASX - By Stock
|
ATH Biotech |
Re:
What to hopefully look forward too
|
|
Mateo335
|
39 |
11K |
12 |
19/08/24 |
19/08/24 |
ASX - By Stock
|
39
|
11K
|
12
|
|
ASX - By Stock
|
ATH Biotech |
Re:
Share Cafe webinar 9th August
|
|
Mateo335
|
10 |
3.6K |
10 |
11/08/24 |
11/08/24 |
ASX - By Stock
|
10
|
3.6K
|
10
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Mateo335
|
73 |
17K |
1 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
73
|
17K
|
1
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Mateo335
|
73 |
17K |
6 |
05/08/24 |
05/08/24 |
ASX - By Stock
|
73
|
17K
|
6
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Mateo335
|
73 |
17K |
4 |
31/07/24 |
31/07/24 |
ASX - By Stock
|
73
|
17K
|
4
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Mateo335
|
169 |
48K |
10 |
27/07/24 |
27/07/24 |
ASX - By Stock
|
169
|
48K
|
10
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Mateo335
|
169 |
48K |
5 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
169
|
48K
|
5
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Mateo335
|
169 |
48K |
6 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
169
|
48K
|
6
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Mateo335
|
169 |
48K |
2 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
169
|
48K
|
2
|
|
ASX - By Stock
|
ATH |
Re:
Good to look at the reference study by Wenning et al
|
|
Mateo335
|
8 |
2.6K |
5 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
8
|
2.6K
|
5
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Mateo335
|
169 |
48K |
3 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
169
|
48K
|
3
|
|
ASX - By Stock
|
ATH |
Re:
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
|
|
Mateo335
|
169 |
48K |
13 |
18/07/24 |
18/07/24 |
ASX - By Stock
|
169
|
48K
|
13
|
|
ASX - By Stock
|
IMU |
Re:
IMUOE's
|
|
Mateo335
|
142 |
62K |
0 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
142
|
62K
|
0
|
|
Charts
|
IMU Biotech |
Re:
IMUGENE CHART. TA only
|
|
Mateo335
|
34K |
17M |
2 |
28/09/23 |
28/09/23 |
Charts
|
34K
|
17M
|
2
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Share Purchase Plan Closing Date Extended
|
|
Mateo335
|
700 |
250K |
24 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
700
|
250K
|
24
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Share Purchase Plan Closing Date Extended
|
|
Mateo335
|
700 |
250K |
1 |
20/09/23 |
20/09/23 |
ASX - By Stock
|
700
|
250K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Share Purchase Plan Closing Date Extended
|
|
Mateo335
|
700 |
250K |
1 |
17/09/23 |
17/09/23 |
ASX - By Stock
|
700
|
250K
|
1
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Share Purchase Plan Closing Date Extended
|
|
Mateo335
|
700 |
250K |
1 |
17/09/23 |
17/09/23 |
ASX - By Stock
|
700
|
250K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Change of Director's Interest Notice - J Basile
|
|
Mateo335
|
29 |
10K |
9 |
15/09/23 |
15/09/23 |
ASX - By Stock
|
29
|
10K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Change of Director's Interest Notice - J Basile
|
|
Mateo335
|
29 |
10K |
7 |
14/09/23 |
14/09/23 |
ASX - By Stock
|
29
|
10K
|
7
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
16 |
10/09/23 |
10/09/23 |
ASX - By Stock
|
12K
|
5.5M
|
16
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
6 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
12K
|
5.5M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
15 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
12K
|
5.5M
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
9 |
05/09/23 |
05/09/23 |
ASX - By Stock
|
12K
|
5.5M
|
9
|
|
Charts
|
IMU Biotech |
Re:
IMUGENE CHART. TA only
|
|
Mateo335
|
34K |
17M |
0 |
01/09/23 |
01/09/23 |
Charts
|
34K
|
17M
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Ann: S&P DJI Announces September 2023 Quarterly Rebalance
|
|
Mateo335
|
49 |
23K |
23 |
01/09/23 |
01/09/23 |
ASX - By Stock
|
49
|
23K
|
23
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Mateo335
|
26K |
13M |
8 |
31/08/23 |
31/08/23 |
ASX - By Stock
|
26K
|
13M
|
8
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Mateo335
|
26K |
13M |
1 |
29/08/23 |
29/08/23 |
ASX - By Stock
|
26K
|
13M
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Investor presentation, 28 August 2023
|
|
Mateo335
|
22 |
11K |
11 |
28/08/23 |
28/08/23 |
ASX - By Stock
|
22
|
11K
|
11
|
|
ASX - By Stock
|
IMU |
Re:
Why IMU is a multi multi bagger
|
|
Mateo335
|
26K |
13M |
15 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
26K
|
13M
|
15
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
2 |
22/08/23 |
22/08/23 |
ASX - By Stock
|
12K
|
5.5M
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
24 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
12K
|
5.5M
|
24
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Mateo335
|
1.3K |
720K |
2 |
10/08/23 |
10/08/23 |
ASX - By Stock
|
1.3K
|
720K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Mateo335
|
1.3K |
720K |
6 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
1.3K
|
720K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Neuren Media and Analyst Coverage
|
|
Mateo335
|
1.3K |
720K |
21 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
1.3K
|
720K
|
21
|
|
ASX - By Stock
|
NEU |
Re:
Phelan-McDermid Syndrome
|
|
Mateo335
|
97 |
45K |
32 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
97
|
45K
|
32
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
2 |
04/08/23 |
04/08/23 |
ASX - By Stock
|
12K
|
5.5M
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
18 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
12K
|
5.5M
|
18
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
17 |
03/08/23 |
03/08/23 |
ASX - By Stock
|
12K
|
5.5M
|
17
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
5 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
12K
|
5.5M
|
5
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Q2 2023 quarterly activity and cash flow report
|
|
Mateo335
|
73 |
31K |
12 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
73
|
31K
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Q2 2023 quarterly activity and cash flow report
|
|
Mateo335
|
73 |
31K |
6 |
31/07/23 |
31/07/23 |
ASX - By Stock
|
73
|
31K
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
Mateo335
|
677 |
330K |
18 |
29/07/23 |
29/07/23 |
ASX - By Stock
|
677
|
330K
|
18
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
6 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
12K
|
5.5M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren and Acadia expand global partnership for trofinetide
|
|
Mateo335
|
153 |
69K |
9 |
26/07/23 |
26/07/23 |
ASX - By Stock
|
153
|
69K
|
9
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
Mateo335
|
12K |
5.5M |
6 |
23/07/23 |
23/07/23 |
ASX - By Stock
|
12K
|
5.5M
|
6
|
|
ASX - By Stock
|
NEU |
Re:
Acadia
|
|
Mateo335
|
677 |
330K |
46 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
677
|
330K
|
46
|
|
ASX - By Stock
|
NEU |
Re:
Phelan-McDermid Syndrome
|
|
Mateo335
|
97 |
45K |
8 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
97
|
45K
|
8
|
|